News Search Results
Apr 16, 2026, 08:00 ET Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics/bio-therapeutics
More news about: Piramal Pharma Solutions
Apr 15, 2026, 12:05 ET Sharp HealthCare Launches New Apple Vision Pro Study in Eye Microsurgery
care," said Dr. Korn.Addressing Longstanding Surgical ChallengesFor decades, surgeons across multiple specialties including ophthalmology, neurosurgery, otolaryngology, and hand surgery have relied on optical microscopes to perform delicate procedures. While these systems remain the
More news about: Sharp HealthCare
Apr 14, 2026, 10:05 ET Study Reveals How Mice Can Quickly Identify Odors
investigator Shy Shoham, PhD.Dr. Shoham, director of the Tech4Health Institute at NYU Langone Health and a professor in the neuroscience and ophthalmology departments at NYU Grossman School of Medicine, said the team's research raises fundamental questions about the role of the cortex in processing
More news about: NYU Langone Health System
Apr 14, 2026, 07:00 ET Cardinal Health report highlights growing momentum to expand advanced therapies into community care settings
Oncology remains the dominant therapeutic area, though innovation is accelerating across additional disease states such as neurology, rheumatology, ophthalmology and cardiology, among others. Today, most oncology advanced therapies are still administered in inpatient academic or health system settings, but
More news about: Cardinal Health
Apr 13, 2026, 07:00 ET InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.Forward-Looking
More news about: InMode LTD.
Apr 10, 2026, 09:00 ET Consumers' Vision Care Decisions Clouded by Costs, According to New Study from CareCredit, a Synchrony Solution
for only 5% of actual LASIK patients. This represents a substantial segment of the population not pursuing the vision care they desire."In ophthalmology practices, where procedures like LASIK are common, 59% of patients cite cost as their main concern, with 64% of those who decide to move forward
More news about: Synchrony
Apr 10, 2026, 06:59 ET Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C., April 10-13, 2026.The presentations will include data across various areas of ophthalmology, including full results from VEGA-3, a Phase 3 study evaluating MR-141 (phentolamine ophthalmic solution 0.75%) for presbyopia; results from a Phase
More news about: Viatris Inc.
Apr 09, 2026, 20:00 ET Immune Resetting: B-Cell Mediated & Beyond Summit 2026 Oral Presentation: Innovent Biologics Announces Pre-Clinical Results of IBI3055, a Tri-specific T Cell Engager Targeting Autoimmune Diseases
that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, presented for the first time the preclinical data of IBI3055, a proprietary anti-CD19/BCMA/CD3 tri-specific T cell
More news about: Innovent Biologics
Apr 09, 2026, 15:26 ET Powered Research at ARVO 2026
David Culp Purpose The New Zealand White (albino) and Dutch Belted (pigmented) rabbits are commonly used in ophthalmology research because their eye sizes are more comparable to human eyes, making study results more translatable, especially in models of corneal surface
More news about: Powered Research, LLC
Apr 07, 2026, 16:25 ET At ASCRS/ASOA 2026, the Saffron Solution Exposes the Hidden Operational Leaks Costing Ophthalmology Practices Growth, Access, and Revenue
As ASCRS and ASOA 2026 begin, a new model for ophthalmology practices emerges—focused on eliminating operational gaps, improving patient access, and driving measurable growthWASHINGTON, April 7, 2026 /PRNewswire/ --
More news about: Maandukya Corporation
Apr 07, 2026, 10:06 ET ZEISS to Celebrate Opening of Huntersville, North Carolina Quality Excellence Center
assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture
More news about: Carl Zeiss Industrial Quality Solutions, LLC
Apr 07, 2026, 09:00 ET New Study Shows Increasing Value of Real-World Data (RWD) in Clinical Trials
data (RWD). Researchers interviewed leaders at 18 pharmaceutical, biotechnology, and contract research organizations (CRO) focused on oncology, ophthalmology, urology, neurology, and dermatology therapeutic areas.Participating companies reported using RWD/RWE to support drug development through
More news about: Verana Health
Apr 07, 2026, 08:49 ET Holland Foundation for Sight Restoration Announces Partnership with Illinois Eye and Ear Infirmary at the University of Illinois Chicago
Dr. Ali R. Djalilian, Searls III/Schenk Professor of Ophthalmology and Co-Director of the Cornea and External Disease Service in the UIC Department of Ophthalmology and Visual Sciences will lead the newly established Center of Excellence. He is a recognized authority
More news about: Holland Foundation for Sight Restoration
Apr 06, 2026, 13:10 ET Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines
while applying its AlloSCOPE "5D" manufacturing process to reduce production costs, with the company's broader pipeline also including the OpRegen ophthalmology program in Phase 2a development under a worldwide collaboration with Roche and Genentech.Eledon Pharmaceuticals (NASDAQ:
More news about: USA News Group
Apr 06, 2026, 09:00 ET AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
not only vision but also daily functioning with symptoms like double vision and eye bulging," said Dr. Madhura A. Tamhankar, M.D., professor of ophthalmology and neurology at the Scheie Eye Institute, University of Pennsylvania. "Expanding administration options through subcutaneous delivery opens the
More news about: Amgen
Apr 03, 2026, 12:19 ET Doheny Eye Institute Welcomes Alicia Cleaver as Chief Development Officer with Support from Envision Consulting
Chief Development Officer. Cleaver joins Doheny at a pivotal time as the Institute continues to expand its impact as a world-renowned leader in ophthalmology.
More news about: Envision Consulting
Apr 02, 2026, 09:00 ET ZEISS advances connected cataract and refractive workflows with new digital, AI and surgical innovations at ASCRS
and enable post-LVC management of cataract patients.Commercial Availability of Human-Verified AI-powered Patient Engagement for the Ophthalmology Practice Workflow: The ZEISS VisioGen™ captures patient demand, answers inquiries with clinical oversight, and supports conversion into
More news about: Carl Zeiss Meditec AG
Apr 02, 2026, 09:00 ET ZEISS advances connected cataract and refractive workflows with new digital, AI and surgical innovations at ASCRS
and enable post-LVC management of cataract patients.Commercial Availability of Human-Verified AI-powered Patient Engagement for the Ophthalmology Practice Workflow: The ZEISS VisioGen™ captures patient demand, answers inquiries with clinical oversight, and supports conversion into
More news about: Carl Zeiss Meditec AG
Apr 02, 2026, 07:33 ET NUHS CHARTS NEW ERA OF PERSONALISED CARE WITH GENOMICS AND DATA-GUIDED BREAKTHROUGHS
Foundation, the launch of the new Centre brings together NUHS's expertise across different specialties such as oncology, cardiology, nephrology, ophthalmology, neurology, infectious diseases and more, expanding genomics testing beyond rare paediatric conditions.Situated within the National University
More news about: National University Health System (NUHS)
Apr 02, 2026, 03:00 ET Lupin Completes Acquisition of VISUfarma
LPCIN) announced the completion of its acquisition of VISUfarma B.V. (VISUfarma), a leading European specialty pharmaceutical company focused on ophthalmology, from GHO Capital Partners LLP (GHO). The acquisition represents a significant milestone in Lupin's strategy to expand its specialty care portfolio
More news about: Lupin Limited
Apr 02, 2026, 03:00 ET Lupin Completes Acquisition of VISUfarma
LPCIN) announced the completion of its acquisition of VISUfarma B.V. (VISUfarma), a leading European specialty pharmaceutical company focused on ophthalmology, from GHO Capital Partners LLP (GHO). The acquisition represents a significant milestone in Lupin's strategy to expand its specialty care portfolio
More news about: Lupin Limited
Apr 01, 2026, 10:00 ET SightMD Welcomes Dr. Jack Klenda, MD to Johnson City Location
www.SightMD.com or call (607) 214 - 2824.SightMD New York is actively seeking ophthalmology professionals who are interested in joining its outstanding team. If you are an ophthalmology practice owner interested in merging or selling your practice, please contact the Chief Medical Officer,
More news about: SightMD
Apr 01, 2026, 07:00 ET Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness
Veteran ophthalmology executive with over 30 years of experience spanning R&D, manufacturing, quality, commercial strategy, and franchise leadershipFormer Vice President and Global Head of Retina at Alcon, with deep experience building and scaling
More news about: Nanoscope Therapeutics
Mar 31, 2026, 10:14 ET i-Lumen Scientific Receives FDA Approval of IDE to Initiate U.S. Enrollment in i-SIGHT2 Clinical Study for dry AMD
Minn., March 31, 2026 /PRNewswire/ -- i-Lumen Scientific, Inc., a leader in energy-based innovations for ophthalmology, and its non-invasive bioelectric stimulation therapy for the treatment of intermediate to advanced dry age-related macular degeneration (AMD) today
More news about: i-LUMEN SCIENTIFIC, Inc.
Mar 31, 2026, 10:14 ET i-Lumen Scientific Receives FDA Approval of IDE to Initiate U.S. Enrollment in i-SIGHT2 Clinical Study for dry AMD
Minn., March 31, 2026 /PRNewswire/ -- i-Lumen Scientific, Inc., a leader in energy-based innovations for ophthalmology, and its non-invasive bioelectric stimulation therapy for the treatment of intermediate to advanced dry age-related macular degeneration (AMD) today
More news about: i-LUMEN SCIENTIFIC, Inc.